GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » Capex-to-Operating-Income

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Capex-to-Operating-Income : 0.00 (As of Dec. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Eucrates Biomedical Acquisition Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Eucrates Biomedical Acquisition's Capital Expenditure for the three months ended in Dec. 2022 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2022 was $-0.26 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Eucrates Biomedical Acquisition Capex-to-Operating-Income Historical Data

The historical data trend for Eucrates Biomedical Acquisition's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eucrates Biomedical Acquisition Capex-to-Operating-Income Chart

Eucrates Biomedical Acquisition Annual Data
Trend Dec20 Dec21 Dec22
Capex-to-Operating-Income
- - -

Eucrates Biomedical Acquisition Quarterly Data
Aug20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Eucrates Biomedical Acquisition's Capex-to-Operating-Income

For the Shell Companies subindustry, Eucrates Biomedical Acquisition's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eucrates Biomedical Acquisition's Capex-to-Operating-Income Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Eucrates Biomedical Acquisition's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Eucrates Biomedical Acquisition's Capex-to-Operating-Income falls into.



Eucrates Biomedical Acquisition Capex-to-Operating-Income Calculation

Eucrates Biomedical Acquisition's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -0.699
=N/A

Eucrates Biomedical Acquisition's Capex-to-Operating-Income for the quarter that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -0.263
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eucrates Biomedical Acquisition  (NAS:EUCRU) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Eucrates Biomedical Acquisition Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
250 West 55th Street, Suite 13D, New York, NY, USA, 10019
Website
Eucrates Biomedical Acquisition Corp is a blank check company.
Executives
Stelios Papadopoulos director, 10 percent owner 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
William I Campbell director 270 PARK AVENUE, NEW YORK NY 10017
Nina B. Shapiro director 2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538
Parag Saxena director, 10 percent owner, officer: Chief Executive Officer 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Daphne Karydas director 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Atanuu Agarrwal officer: Vice President 250 WEST 55TH STREET, NEW YORK NY 10019
Gonzalo Cordova officer: Chief Financial Officer 250 WEST 55TH STREET, NEW YORK NY 10019
Eucrates Llc 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Shrikant Sathe officer: Senior Vice President C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Evangelos Vergetis director, officer: President, COO C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Amitabh Singhal director C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Headlines